$ALM

Almirall, S.A.: Almirall H1 2026 Results

Almirall (ALM) reported H1 2026 results: net sales rose 7.5% YoY to €602.7m and EBITDA increased 23.7% to €150.7m. European Dermatology net sales grew 18.1% to €341.9m, led by biologics Ebglyss (€84.5m, +88.2%) and Ilumetri (€125.2m, +10.5%). Full-year 2026 guidance reiterated: 9-12% net sales growth and €270m-€290m EBITDA.

Original reporting
Published Jul 24, 2026, 5:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 24, 2026, 5:56 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$ALM
Bullish
medium confidence
Mentioned
$ALM
Relevance
8/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$ALMBullishMed
01

Why it matters

Traders can use the H1 financials and reiterated 2026 Net Sales growth (9% to 12%) and EBITDA (€270MM to €290MM) to update near-term expectations and valuation models for the company’s earnings trajectory.

02

Market read

A guidance-reiterating H1 beat with detailed segment and biologics growth provides a fresh datapoint for estimate revisions and sentiment.

03

What to watch

The article does not provide cash flow, margin drivers, or any risk items (pricing, competition, reimbursement), which could temper how much the market extrapolates from H1.

Relevance 8/10Novelty 7/10Timing: pre-market today, ahead of further analyst estimate updates after the H1 print

Background

Almirall is a medical dermatology pharmaceutical company with key biologics including Ebglyss and Ilumetri, and a broader portfolio across dermatology indications.

Company-level read

Ticker impact

$ALMBullishMedium confidence
Context

Almirall reported H1 2026 Net Sales up 7.5% to €602.7MM and EBITDA up 23.7% to €150.7MM, reiterating 2026 guidance.

Expected impact

Moderately positive bias for the next few sessions as traders reprice 2026 EBITDA expectations around the reiterated €270MM to €290MM range.

Evidence & confidence

The article provides concrete H1 financials plus unchanged guidance, which typically drives sentiment and estimate revisions, though it is not a surprise event like an acquisition or regulatory decision.

Market effects

Reinforces demand and execution strength in medical dermatology, potentially supporting sentiment for dermatology-focused pharma peers.

Highlights continued European Dermatology growth, which may influence regional healthcare sector positioning.

Global biologics portfolio growth and R&D pipeline updates can affect broader investor appetite for dermatology innovation stories.

Counterpoint

Guidance is reiterated rather than raised, so upside may be limited if the market expected a beat beyond the stated ranges.

Key entities

  • Almirall, S.A.

    Reported H1 2026 results and reiterated full-year 2026 guidance; highlighted European Dermatology and biologics growth.

  • Ebglyss

    Lebrikizumab, systemic atopic dermatitis treatment; Net Sales €84.5MM, up 88.2% YoY in H1 2026.

  • Ilumetri

    Tildrakizumab, systemic plaque psoriasis treatment; Net Sales €125.2MM, up 10.5% YoY in H1 2026.

  • Certest Biotec

    Announced strategic research collaboration and licensing agreement for rare dermatologic diseases and recurrent cutaneous conditions.

Related articles

$ALMMedAI 8/10

Almonty Industries Reports Second Quarter 2026 Financial Results

Almonty Industries (Nasdaq: ALM) reported Q2 2026 results: revenue rose 498% year over year to $43.0 million, with net income of $181.8 million and adjusted EBITDA of $17.6 million. The company closed an oversubscribed $800 million 2.25% convertible notes offering and reported $1.2 billion cash at June 30, 2026. It also amended its GTP offtake agreement, extending it 6 years and raising volumes and pricing.

$BMMMed

The Critical Metal at the Center of America’s Next Supply-Chain Crisis

The article says tungsten has outperformed gold, silver and copper over the past year and that the U.S. has not mined tungsten since 2015, while China supplies about 80% of global tungsten and nearly 90% of processing. It notes a U.S. defense rule from Jan 1, 2027 banning tungsten routed through China. It highlights Blue Moon Metals (TSXV: MOON, NASDAQ: BMM) acquiring 33 tungsten and antimony projects near its Springer complex, with consideration including 2.8M shares, $5.0M cash, and a 1% NSR r

$ALMMed

Almonty Industries: A 490-Million-Dollar Contract Offers Ballast as the Stock Tests Key Support

Almonty Industries’ shares fell to C$18.81, down 5.52% on Friday and about 44% below its April 52-week high, as the stock tests support near C$18.00. The company began processing at its Sangdong mine in South Korea and extended an offtake with Global Tungsten & Powders for 21 years, with higher volumes and prices, expected to add at least US$30m annual contract revenue and about US$490m total.

$ALMMed

Almonty Industries Navigates a Pivotal Week: Production Milestones Meet Exchange Overhaul

Almonty Industries said it will delist from the Toronto Stock Exchange after July 31 and from the ASX after CHESS depositary interests end Aug. 28, with ASX delisting effective Sept. 1, citing low Australian volumes. Shares closed C$18.81, down 5.52% on Friday. Sangdong processing began July 1, and a 21-year offtake with Global Tungsten & Powders was expanded by 40% to about US$490 million potential revenue.